Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.
Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Fernando Martínez de Juan(Fundación Instituto Valenciano de Oncología), Javier Gállego(Hospital General Universitario de Elche), Carles Pericay(University Hospital Mútua de Terrassa), Monique Maas(The Netherlands Cancer Institute), Marcos Melián, Joan Maurel(Breast Cancer Research Foundation), Ferrán Losa, Ana Vivancos(Vall d'Hebron Institute of Oncology), Ana Virgili(Hospital de Sant Pau), Ruth Vera(Complejo Hospitalario de Navarra), Nuria Rodrı́guez-Salas(Hospital Universitario La Paz), Jaume Capdevila(Vall d'Hebron Institut de Recerca), Juan Ramón Ayuso(Hospital Clínic de Barcelona), Manuel Valladares(American Society of Clinical Oncology)
Cited by 3
Related Papers
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
|Cancer Research|2017|480